MediciNova的MN-001（tipelukast）NASH摘要入选了最新会议在波士顿

StephenW

LA JOLLA, Calif., Oct 06, 2014 (GLOBE NEWSWIRE via COMTEX) --

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market MNOV, +12.67% and the JASDAQ Market of the Tokyo Stock Exchange (code number:4875), today announced that it has been invited to and will present data on MN-001 (tipelukast) during the late-breaking poster session at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), to be held November 7 – 11 in Boston.

In August 2014, MediciNova announced positive results from a mouse model that examined the potential clinical efficacy of MN-001 for the treatment of advanced NASH (nonalcoholic steatohepatitis with fibrosis). In this presentation, MediciNova will present detailed information about the effectiveness of MN-001 (tipelukast) in the NASH model.

Presentation details are as follows:

Presentation: "MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression in an advanced NASH (nonalcoholic steatohepatitis) model"

Session Date: Monday, November 10, 2014

Session: Late-Breaking Poster Session

Room: John B. Hynes Convention Center, Hall C

About NASH (nonalcoholic steatohepatitis)

Nonalcoholic steatohepatitis (NASH) is a condition in which there is fat in the liver along with inflammation and damage to liver cells. NASH is a common liver disease that resembles alcoholic liver disease but occurs in people who drink little or no alcohol. According to the U.S. National Digestive Diseases Information Clearinghouse (NDDIC), NASH prevalence in the U.S. is 2-5%, and an additional 10-20% of Americans have "fatty liver." The underlying cause of NASH is unclear, but it most often occurs in persons who are middle-aged and overweight or obese. Many patients with NASH have elevated serum lipids, diabetes or pre-diabetes. Progression of NASH can lead to liver cirrhosis. Liver transplantation is the only treatment for advanced cirrhosis with liver failure. At this time, there is no treatment for NASH.

About MN-001

MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound which exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development and MN-001's inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models.

Previously, MediciNova evaluated MN-001 for its potential clinical efficacy in asthma and had positive Phase 2 results. MN-001 has been exposed to more than 600 subjects and considered generally safe and well-tolerated.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a commercial focus on the U.S. market. MediciNova's current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive MS, ALS and substance dependence (e.g. Methamphetamine dependence, opioid dependence) and MN-001 (tipelukast) for nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF) and other fibrotic disease. MediciNova's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbations of asthma and MN-029 (denibulin) for solid tumor cancers. MediciNova is engaged in strategic partnering and other potential funding discussions to support further development of its programs. For more information on MediciNova, Inc., please visit www.medicinova.com

StephenW

MediciNova公司是一家生物制药公司，在纳斯达克全球市场上市交易MNOV+12.67％，而东京证券交易所的JASDAQ市场（代号：4875），今天宣布，它已被邀请，并介绍与MN-数据在波士顿的11 - 001（tipelukast）在美国协会的第65届年会肝病（AASLD）的研究的最新海报会议期间，将举行11月7日。

在2014年8月，MediciNova宣布从检查MN-001的潜在的临床疗效先进NASH的治疗（非酒精性脂肪性肝炎与肝纤维化）的小鼠模型中的积极成果。在这个演示中，MediciNova将提出有关的MN-001（tipelukast）在纳什议价模型的有效性的详细信息。

演讲详情如下：

介绍：“MN-001（tipelukast），一种新型的，口服生物利用度的药物，减轻纤维化和炎症，并下调TIMP-1，在高级NASH（非酒精性脂肪性肝炎）模型的胶原蛋白I型和LOXL2 mRNA的表达”

会议日期：星期一，二○一四年十一月一十日

会议：近期发布的海报会议

房：约翰·B·海因斯会议中心C馆

关于NASH（非酒精性脂肪性肝炎）

非酒精性脂肪性肝炎（NASH）是一个条件，其中有脂肪在肝脏中随着炎症和损害肝细胞。纳什类似于酒精性肝病，但发生在人谁喝很少或不含酒精常见的肝脏疾病。据美国国家消化系统疾病信息中心（NDDIC），NASH的发病率在美国是2-5％，而美国人的额外10％-20％有“脂肪肝”。 NASH的根本原因还不清楚，但它常发生在谁是中年超重或肥胖的人。许多NASH患者有升高血脂，糖尿病或糖尿病前期。 NASH进展可导致肝硬化。肝移植是肝功能衰竭晚期肝硬化的唯一治疗方法。在这个时候，有没有治疗NASH。

关于MN-001

MN-001（tipelukast）是一种新型的，口服生物可利用的小分子化合物，该化合物通过几种机制发挥其作用，以产生其抗纤维化和抗炎活性的临床前模型，包括白三烯（LT）受体拮抗作用，抑制磷酸二酯酶（PDE ）（主要是3和4），以及抑制5 - 脂氧合酶（5-LO）。 5-LO / LT途径已被假定为在纤维化的发展和MN-001对5-LO的抑制作用的致病因子和5-LO/ LT途径被认为是一种新颖的方法来治疗纤维化。 MN-001已经显示为下调基因，促进纤维化包括LOXL2，胶原蛋白类型1和TIMP-1的表达。 MN-001也被示出为下调基因，促进炎症包括CCR2和MCP-1的表达。此外，组织学数据表明，MN-001减少纤维化的多种动物模型。

此前，MediciNova评估的MN-001其潜在的临床疗效，哮喘和有积极的第二阶段结果。 MN-001已经暴露于超过600个科目，并认为一般是安全且耐受性良好。

关于MediciNova

MediciNova公司是一家公开上市的生物制药公司，成立于收购和开发新的，小分子疗法为与商业重心在美国市场上尚未满足的医疗需求的疾病治疗。 MediciNova目前的战略是专注于MN-166（异丁司特），神经系统疾病，如进行性MS，ALS和物质依赖（如甲基苯丙胺依赖，阿片类药物依赖）和MN-001（tipelukast），非酒精性脂肪性肝炎（NASH）和特发性肺间质纤维化（IPF）和其他纤维化疾病。 MediciNova的管道还包括MN-221（bedoradrine）用于治疗哮喘和MN-029（denibulin）的实体瘤癌症急性发作的治疗。 MediciNova是一家从事战略伙伴关系和其他潜在的资金进行讨论，以支持其方案的进一步发展。有关MediciNova公司的更多信息，请访问www.medicinova.com